---
title: "Lysergide (DT120) in Generalized anxiety disorder: Limitations of current therapies"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Limitations of current therapies. Topics: Nonresponse to available treatments; Response and remission rates with SSRIs and SNRIs; Delayed onset of antidepressant effect; Adverse effects, adherence, and discontinuation of antidepressants; 4 further topics. 9 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Limitations of current therapies

<a id="heading-2.2.2.1.10"></a>

## 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

### Summary

Up to 50% of patients with GAD have an inadequate response to available agents, and 50 to 67% respond adequately to a first treatment trial. Reported response and remission rates are 60% to 68% and 30% to 36% with SSRIs and 56% to 58% and 31% to 38% with SNRIs; another review gives SSRI response in randomized trials as 60% to 75% against 40% to 60% with placebo. One source advises telling patients that treatment periods of up to 12 weeks may be needed to assess efficacy. SSRI and SNRI discontinuation rates are 20% to 23%, associated with nausea, sexual dysfunction, and slow onset. Across 28 anxiety disorder studies (n=5233), relapse prevalence was 36.4% in placebo groups and 16.4% in antidepressant groups; in 6 GAD studies, the odds ratio for relapse after discontinuation was 4.20 (95% CI 2.42 to 7.28). Benzodiazepines carry a class boxed warning for abuse, addiction, physical dependence, and withdrawal; pregabalin is a Schedule V controlled substance; buspirone efficacy beyond 3 to 4 weeks has not been demonstrated in controlled trials. The prescribing information of escitalopram, paroxetine, venlafaxine extended-release, duloxetine, and alprazolam lists GAD among their indications. The indication lists in the prescribing information of pregabalin, a recommended first-line therapy in one source, and of quetiapine extended-release, a second-line choice in the same source, do not include GAD.

Source: [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/); [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/); [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/); [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/); [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf); [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/); [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class); [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf); [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf); [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf); [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf); [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf); [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf); [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf); [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/); [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.10-2"></a>

### Nonresponse to available treatments

> “Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier.”

Source: [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/)

> “only 50 to 67% of patients show an adequate clinical response after the first treatment trial”

Source: [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/)

> “Many patients do not respond to first-line pharmacological or psychological interventions.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.10-3"></a>

### Response and remission rates with SSRIs and SNRIs

> “However, numerous GAD patients do not achieve remission or response despite adequate dose and duration of SSRIs and SNRIs.”
> “Regularly, the rates of response and remission for GAD patients treated with SSRIs are 60%–68% and 30%–36%”
> “In addition, GAD patients treated with SNRIs have demonstrated response and remission rates of 56%–58% and 31%–38%”

Source: [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)

> “Randomized-controlled trials suggest that 60-75% of patients respond to SSRIs, compared to 40-60% of patients receiving placebo, with similar response rates for SNRIs and BZs”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.10-4"></a>

### Delayed onset of antidepressant effect

> “the gradual development, over 1 week or more, of the full anxiolytic effect”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

> “It should be emphasised that treatment response is not immediate; that a transient worsening of symptoms can sometimes occur; that prolonged courses are needed to maintain an initial treatment response”
> “Advise the patient that treatment periods of up to 12 weeks may be needed to assess efficacy”
> “but recognise that an absence of clinical benefit within four weeks warns that a response to unchanged treatment is unlikely”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.10-5"></a>

### Adverse effects, adherence, and discontinuation of antidepressants

> “Additionally, several GAD patients discontinue the antidepressant therapy. Based on recent evidences, the overall discontinuation rates for SSRIs and SNRIs are 20%–23%”
> “The low acceptability and tolerability of SSRIs and SNRIs are possibly associated with unfavorable side effects of SSRIs and SNRIs including nausea and sexual dysfunction, as well as slow onset of their action.”

Source: [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)

> “Some of these side effects are similar to the symptoms of anxiety, which can lead to premature termination before the medication has had enough time to reach maximum efficacy”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

> “For these reasons, many of those who might benefit from treatment do not receive it, and many of those who do undergo treatment stop it early because of the emergence of unwanted effects.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.10-6"></a>

### Patient concerns about tolerance and dependence

> “Others fear developing a tolerance or becoming dependent on medication, and so are reluctant to start, let alone continue, pharmacological treatment.”
> “dependence can occur (especially in predisposed patients) with prolonged use: and it is hard to identify those patients at risk of developing long-term problems”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

> “Common concerns about taking medication, such as fears of addiction, should be addressed.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.10-7"></a>

### Relapse after antidepressant discontinuation

> “The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year.”
> “Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89).”
> “Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group”

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

| Subgroup | Studies | Odds ratio for relapse after discontinuation (95% CI) |
| --- | --- | --- |
| Generalised anxiety disorder (DSM-IV) | “6” | “4.20 (2.42 to 7.28)” |

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

> “Although approximately 16% of patients relapse despite continued use of antidepressants, discontinuing antidepressants before one year leads to symptom relapse in up to 50% of patients being treated with an SSRI or SNRI.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “If the drug is effective, advise the person to continue taking it for at least a year as the likelihood of relapse is high.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.10-8"></a>

### Treatment-resistant anxiety disorder: consensus definition

> “The definition of pharmacological treatment resistance in anxiety disorders should rest on at least two failed trials of pharmacological monotherapy with first‐line agents approved for the treatment of anxiety disorders and recommended by guidelines (two different classes, e.g. one SSRI plus one SNRI, clomipramine or pregabalin, in the case of GAD) using at least the minimal approved dose, for the duration of at least 6‐8 weeks each, ideally with documented therapy adherence.”

Source: [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/)

> “Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness.”
> “This disorder is reportedly frequently under-recognized with less than one-third of patients being adequately treated”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.10-9"></a>

### Evidence for combination and augmentation strategies

> “evidence for the effectiveness of combination treatments is lacking and”
> “side effects and interactions are more likely when combining and augmenting antidepressants.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
